CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) major shareholder 5Am Partners Vi, Llc bought 600,000 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was bought at an average cost of $30.00 per share, for a total transaction of $18,000,000.00. Following the acquisition, the insider now owns 3,953,990 shares of the company’s stock, valued at approximately $118,619,700. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
CinCor Pharma Trading Down 0.8 %
CINC stock traded down $0.28 on Wednesday, reaching $34.92. 136,465 shares of the company’s stock were exchanged, compared to its average volume of 204,162. The stock has a fifty day moving average of $22.20 and a 200-day moving average of $21.40. CinCor Pharma, Inc. has a twelve month low of $13.00 and a twelve month high of $43.15.
CinCor Pharma (NASDAQ:CINC – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). As a group, sell-side analysts forecast that CinCor Pharma, Inc. will post -2.38 EPS for the current fiscal year.
Analyst Ratings Changes
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG acquired a new position in CinCor Pharma during the first quarter worth $38,000. Amalgamated Bank acquired a new stake in CinCor Pharma in the first quarter valued at $40,000. California State Teachers Retirement System acquired a new stake in CinCor Pharma in the first quarter valued at $87,000. JPMorgan Chase & Co. acquired a new stake in CinCor Pharma in the first quarter valued at $95,000. Finally, American International Group Inc. acquired a new stake in CinCor Pharma in the first quarter valued at $101,000. Institutional investors and hedge funds own 52.53% of the company’s stock.
About CinCor Pharma
CinCor Pharma, Inc, a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases.
- Get a free copy of the StockNews.com research report on CinCor Pharma (CINC)
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe’s Stands Out Amid Q2 Retail Reports
- Target’s Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
Receive News & Ratings for CinCor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CinCor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.